Liraglutide for managing overweight and obesity: Final appraisal document

DRAFT guidance recommends liraglutide as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, providing certain criteria are met.

SPS commentary:

Proposed criteria are as follows:

 

  • BMI ≥35 kg/m2 (adjust accordingly using lower thresholds for members of minority ethnic groups known to be at equivalent risk of consequences of obesity at lower BMI than white population) and
  • have non-diabetic hyperglycaemia (HbA1c 42-47 mmol per mol [6.0 to 6.4%] or a fasting plasma glucose level of 5.5 to 6.9 mmol per litre) and
  • have high risk of CVD based on risk factors such as hypertension and dyslipidaemia and
  • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and
  • company provides it according to the commercial arrangement

National Institute for Health and Care Excellence